Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840770 | 1.00 | CTSB (0.47) | CTSBCTSSCTSKHTTRAB9A | |
| SCHEMBL5677871 | 0.86 | EPHX2 (0.47) | CTSBCTSSCTSKALDH1A1 | |
| SCHEMBL1486257 | 0.86 | CYP2C9 (0.45) | CTSBCTSSCTSKHTTKMT2A | |
| SCHEMBL5675372 | 0.86 | EPHX2 (0.47) | CTSBCTSSCTSKHTTKMT2A | |
| SCHEMBL5675876 | 0.86 | CTSB (0.43) | CTSBCTSSCTSKKMT2AMEN1 | |
| SCHEMBL5674323 | 0.86 | EPHX2 (0.47) | CTSBCTSSCTSKKMT2AMEN1 | |
| SCHEMBL5674238 | 0.83 | CYP1A2 (0.48) | CTSBCTSSCTSKKMT2AMEN1 | |
| SCHEMBL1841878 | 0.82 | ALDH1A1 (0.54) | CTSBCTSSCTSKHTTRAB9A | |
| SCHEMBL7533918 | 0.82 | CTSB (0.40) | CTSBCTSSCTSKRAB9ANPC1 | |
| SCHEMBL5674494 | 0.82 | CTSK (0.40) | CTSBCTSSCTSKSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009425-B1 | ALPHA-OXOACYLAMINOCAPROLACTAM | SEIKAGAKU KOGYO CO LTD (JP) | 2018-06-06 | — | — | EP | disclosed |
| EP-3009425-B1 | ALPHA-OXOACYLAMINOCAPROLACTAM | SEIKAGAKU KOGYO CO LTD (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-9562042-B2 | α-oxoacyl amino-caprolactam | SEIKAGAKU CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562042-B2 | α-oxoacyl amino-caprolactam | SEIKAGAKU CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562042-B2 | α-oxoacyl amino-caprolactam | SEIKAGAKU CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160130266-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | SEIKAGAKU CORPORATION (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130266-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | SEIKAGAKU CORPORATION (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130266-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | SEIKAGAKU CORPORATION (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3009425-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | Seikagaku Corporation (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009425-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | Seikagaku Corporation (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2036920-A1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2009-03-18 | — | — | EP | disclosed |
| CN-101370773-A | Cycloalkanecarboxamide derivative and method for producing same | SEIKAGAKU KOGYO CO LTD (JP) | 2009-02-18 | — | — | CN | disclosed |
| EP-1975162-A1 | OXAZOLONE DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2008-10-01 | — | — | EP | disclosed |
| EP-1972636-A1 | CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
| EP-1972615-A1 | CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131661-A1 | Oxazolone Derivatives | CTSK, CTSZ, CTSV | CTSB 5/4885CTSS 4/4885CTSK 1/4885 |
| US-20160130266-A1 | ALPHA-OXOACYL AMINO-CAPROLACTAM BODY | ANPEP, COL2A1, PTMS | CTSB 468/4885CTSS 661/4885CTSK 256/4885 |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | CTSK, CTSS, CTSV | CTSB 6/4885CTSS 2/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.